PCSK9 抗体 (AA 153-380)
-
- 抗原 See all PCSK9 抗体
- PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
-
抗原表位
- AA 153-380
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This PCSK9 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)
- 交叉反应
- 人
- 纯化方法
- >95%, Protein G purified
- 免疫原
- Recombinant Human Proprotein convertase subtilisin/kexin type 9 protein (153-380AA)
- 亚型
- IgG
- Top Product
- Discover our top product PCSK9 Primary Antibody
-
-
- 应用备注
- Recommended dilution: WB:1:1000-1:5000, IHC:1:500-1:1000, IF:1:50-1:200,
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4 - 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C,-80 °C
- 储存方法
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- 抗原
- PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))
- 别名
- PCSK9 (PCSK9 产品)
- 别名
- FH3 antibody, HCHOLA3 antibody, LDLCQ1 antibody, NARC-1 antibody, NARC1 antibody, PC9 antibody, AI415265 antibody, AI747682 antibody, Narc1 antibody, proprotein convertase subtilisin/kexin type 9 antibody, proprotein convertase subtilisin/kexin type 9 L homeolog antibody, PCSK9 antibody, pcsk9.L antibody, pcsk9 antibody, Pcsk9 antibody
- 背景
-
Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Aliases: Convertase subtilisin/kexin type 9 preproprotein antibody, FH3 antibody, HCHOLA3 antibody, Hypercholesterolemia autosomal dominant 3 antibody, LDLCQ1 antibody, NARC 1 antibody, NARC-1 antibody, NARC1 antibody, Neural apoptosis regulated convertase 1 antibody, Neural apoptosis-regulated convertase 1 antibody, PC 9 antibody, PC9 antibody, PCSK 9 antibody, PCSK9 antibody, PCSK9_HUMAN antibody, Proprotein convertase 9 antibody, Proprotein convertase PC9 antibody, Proprotein convertase subtilisin/kexin type 9 antibody, PSEC0052 antibody, Subtilisin/kexin like protease PC9 antibody, Subtilisin/kexin-like protease PC9 antibody
- UniProt
- Q8NBP7
-